Preparation and evaluation of 211at labelled antineoplastic antibodies

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 2, 2007, Pages

  Walte, Almut ^a   Sriyapureddy, Siva Sankar Reddy ^a   Korkmaz, Zekiye ^a   Krull, Doris ^a   Bolte, Oliver ^a   Hofmann, Michael ^b   Meyer, Geerd J ^a   Knapp, Wolfram H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMTUZUMAB AT 211; GEMTUZUMAB OZOGAMICIN; GEMTUZUMAB OZOGAMICIN AT 211; RITUXIMAB; RITUXIMAB AT 211; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; ASTATINE; EPITOPE; GEMTUZUMAB; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL STRAIN HL 60; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; ANIMAL; BINDING COMPETITION; CHEMISTRY; DOSE RESPONSE; METHODOLOGY; TUMOR CELL LINE;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASTATINE; BINDING, COMPETITIVE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; EPITOPES; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; RADIOIMMUNOTHERAPY;

EID: 34548722210     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Vaidyanathan, G., Zalutsky, M.R. Targeted therapy using alpha emitters. Phys. Med. Biol., 41:1915-1931, 1996.
2. Arzneimittel-Kompendium, der Schweiz®. Roche Pharma AG Suisse, Fachinformation MabThera®. Documed AG, 2006.
3. 211At-rituximab against non-Hodgkin's lymphoma cells. Br. J. Cancer, 83:1375-1379, 2000.
4. Wyeth Pharmaceuticals Inc, USA. Product information Mylotarg®. 2006.
5. 211At labeling of proteins. Nucl. Med. Biol. 31:1061-1071, 2004.
6. Zalutsky, M.R., Narula, A.S. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate. Int. J. Rad. Appl. Instrum [A], 39(3):227-232, 1988.
7. Amico, D., Barbui, A.M., Erba, E., Rambaldi, A., Introna, M., Golay, J. Differential response of human myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood, 101:4589-4597, 2003.
8. 111In in humhn myeloid leukemia cells. J. Nucl. Med., 47:827-836, 2006.
9. Xu, Y., Scheinberg, D.A. Elimination of human leukemia by monoclonal antibodies in an athymic nude mouse leukemia model.Clin Cancer Res., 1:1179-1187, 1995.
10. Law, C.L., Cerveny, C.G., Gordon, K.A., Klussman, K., Mixan, B.J., Chace, D.F., Meyer, D.L., Doronina, S.O., Siegall, C.B., Francisco, J.A., Senter, P.D., Wahl, A.F. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin. Cancer. Res., 10:7842-7851, 2004.
11. Vandenbulcke, K., Thierens, H., Offner, F., Janssens, A., de Gelder, V., Bacher, K., Philippe, J., De Vos, F., Dierckx, R., Apostolidis, C., Morgenstern, A., Slegers, G. Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study. Nucl. Med. Commun., 25:1131-1136, 2004.
12. Zalutsky, M.R., Vaidyanathan, G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr. Pharm. Des., 6:1433-1455, 2000.